Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07372625 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
A Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation, sponsored by PMV Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT07372625: Recruiting Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation, sponsored by PMV Pharmaceuticals.
NCT07372625 is a Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation that is actively recruiting participants, run by PMV Pharmaceuticals. The registered enrollment target is 14 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07372625, a Phase 1 study of Advanced Solid Tumors and TP53 Y220C Mutation, is actively recruiting participants, sponsored by PMV Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Primary Outcome
Geometric mean metformin peak concentration (Cmax) when administered with rezatapopt versus metformin alone.
Conditions Studied
Interventions
- DRUG rezatapopt
- DRUG metformin hydrochloride 500 mg tablet
- DRUG rosuvastatin 10 mg tablet
- DRUG repaglinide 0.5 mg tablet
- DRUG midazolam hydrochloride syrup
Study Locations (5)
Texas
- SCRI at Mary Crowley - Dallas
- NEXT Oncology - San Antonio
Colorado
- HealthOne Denver - Denver
Florida
- Florida Cancer Specialists - Orlando
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT07372625 shows while recruiting
NCT07372625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which rezatapopt is the first listed.
NCT07372625 lists 5 locations in 4 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT07372625 about?
NCT07372625 is a clinical study titled "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.". This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.
What is the current status of trial NCT07372625?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-02-04. Estimated completion is 2028-01.
What conditions does trial NCT07372625 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, TP53 Y220C Mutation.
What interventions are being tested in trial NCT07372625?
The interventions under investigation include: rezatapopt (DRUG), metformin hydrochloride 500 mg tablet (DRUG), rosuvastatin 10 mg tablet (DRUG), repaglinide 0.5 mg tablet (DRUG), midazolam hydrochloride syrup (DRUG).
Who is sponsoring clinical trial NCT07372625?
This trial is sponsored by PMV Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07372625 being conducted?
This trial has 5 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07372625's enrollment target sits among peer trials
14 134th of 144 higher than 9 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy